• Mutation; HGNC; HGNC:644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (PubMed=22213130).
  
• Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from child cell line LNCaP clone FGC).
  
• Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from child cell line LNCaP clone FGC).
  
• Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (PubMed=9090379).
  
• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=14518029).
  

CLPUB00410
Horoszewicz J.S., Leong S.S., Chu T.M., Wajsman L.Z., Friedman M., Papsidero L.D., Kim U., Chai L.S., Kakati S., Arya S.K., Sandberg A.A.
The LNCaP cell line -- a new model for studies on human prostatic carcinoma.
(In book chapter) Models for prostate cancer; Murphy G.P. (eds.); pp.115-132; Alan R. Liss; New York; USA (1980)

PubMed=6831420
Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., Murphy G.P.
LNCaP model of human prostatic carcinoma.
Cancer Res. 43:1809-1818(1983)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=2734981; DOI=10.1007/BF00262025
Konig J.J., Kamst E., Hagemeijer A., Romijn J.C., Horoszewicz J.S., Schroder F.H.
Cytogenetic characterization of several androgen responsive and unresponsive sublines of the human prostatic carcinoma cell line LNCaP.
Urol. Res. 17:79-86(1989)

PubMed=8687134
Pandalai P.K., Pilat M.J., Yamazaki K., Naik H., Pienta K.J.
The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth.
Anticancer Res. 16:815-820(1996)

PubMed=9018337; DOI=10.1002/(SICI)1097-0045(19970101)30:1<58::AID-PROS9>3.0.CO;2-H
Webber M.M., Bello D., Quader S.T.A.
Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines.
Prostate 30:58-64(1997)

PubMed=9090379; DOI=10.1038/ng0497-356
Steck P.A., Pershouse M.A., Jasser S.A., Yung W.-K.A., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H.-F., Tavtigian S.V.
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
Nat. Genet. 15:356-362(1997)

PubMed=9460501; DOI=10.1016/S0165-4608(97)00060-5
Nupponen N.N., Hyytinen E.-R., Kallioniemi A.H., Visakorpi T.
Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization.
Cancer Genet. Cytogenet. 101:53-57(1998)

PubMed=10702678; DOI=10.1159/000015432
Pan Y., Kytola S., Farnebo F., Wang N., Lui W.-O., Nupponen N.N., Isola J.J., Visakorpi T., Bergerheim U.S.R., Larsson C.
Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping.
Cytogenet. Cell Genet. 87:225-232(1999)

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H
Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Mol. Carcinog. 28:236-246(2000)

PubMed=11135431; DOI=10.1002/1098-2264(2000)9999:9999<::AID-GCC1076>3.0.CO;2-E
Aurich-Costa J., Vannier A., Gregoire E., Nowak F., Cherif D.
IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: application to the analysis of seven human prostate cell lines.
Genes Chromosomes Cancer 30:143-160(2001)

PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3
Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.
The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: a comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data.
Cancer Genet. Cytogenet. 124:112-121(2001)

PubMed=11304728; DOI=10.1002/pros.1045
van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.
Widely used prostate carcinoma cell lines share common origins.
Prostate 47:36-51(2001)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=12606952; DOI=10.1038/sj.onc.1206247
Clark J., Edwards S., Feber A., Flohr P., John M., Giddings I., Crossland S., Stratton M.R., Wooster R., Campbell C., Cooper C.S.
Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays.
Oncogene 22:1247-1252(2003)

PubMed=12725112; DOI=10.1385/1-59259-372-0:21
Russell P.J., Kingsley E.A.
Human prostate cancer cell lines.
Methods Mol. Med. 81:21-39(2003)

PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)

CLPUB00698
van Bokhoven A.
Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.
Thesis PhD (2004); Katholieke Universiteit Nijmegen; Nijmegen; Netherlands

PubMed=15162376; DOI=10.1002/pros.20031
Liu A.Y., Brubaker K.D., Goo Y.A., Quinn J.E., Kral S., Sorensen C.M., Vessella R.L., Belldegrun A.S., Hood L.E.
Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines.
Prostate 60:98-108(2004)

PubMed=15486987; DOI=10.1002/pros.20158
Zhao H.-J., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D.
Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
Prostate 63:187-197(2005)

PubMed=22213130; DOI=10.1002/pros.22480
Spans L., Atak Z.K., Van Nieuwerburgh F., Deforce D., Lerut E., Aerts S., Claessens F.
Variations in the exome of the LNCaP prostate cancer cell line.
Prostate 72:1317-1327(2012)

PubMed=22278370; DOI=10.1074/mcp.M111.014050; PMCID=PMC3316730
Geiger T., Wehner A., Schaab C., Cox J., Mann M.
Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.
Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=23671654; DOI=10.1371/journal.pone.0063056; PMCID=PMC3646030
Lu Y.-H., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=24587179; DOI=10.1371/journal.pone.0090002; PMCID=PMC3938550
Spans L., Helsen C., Clinckemalie L., Van den Broeck T., Prekovic S., Joniau S., Lerut E., Claessens F.
Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines.
PLoS ONE 9:E90002-E90002(2014)

PubMed=24618588; DOI=10.1371/journal.pone.0091433; PMCID=PMC3950186
Chernobrovkin A.L., Zubarev R.A.
Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.
PLoS ONE 9:E91433-E91433(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26256267; DOI=10.1074/mcp.M115.047928; PMCID=PMC4597149
Shah P., Wang X.-C., Yang W.-M., Toghi Eshghi S., Sun S.-S., Hoti N., Chen L.-J., Yang S., Pasay J., Rubin A., Zhang H.
Integrated proteomic and glycoproteomic analyses of prostate cancer cells reveal glycoprotein alteration in protein abundance and glycosylation.
Mol. Cell. Proteomics 14:2753-2763(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
J. Proteomics 139:77-83(2016)

PubMed=27036029; DOI=10.18632/oncotarget.8456; PMCID=PMC5041979
Kregel S., Chen J.L., Tom W., Krishnan V., Kach J., Brechka H., Fessenden T.B., Isikbay M., Paner G.P., Szmulewitz R.Z., Vander Griend D.J.
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Oncotarget 7:26259-26274(2016)

PubMed=27141528; DOI=10.1016/j.dib.2016.04.001; PMCID=PMC4838930
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Data Brief 7:1302-1305(2016)

PubMed=29194687; DOI=10.1002/pros.23459; PMCID=PMC5768451
Fiandalo M.V., Wilton J.H., Mantione K.M., Wrzosek C., Attwood K.M., Wu Y., Mohler J.L.
Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.
Prostate 78:213-221(2018)

PubMed=29233929; DOI=10.1158/0008-5472.CAN-17-1924; PMCID=PMC5983359
Horning A.M., Wang Y., Lin C.-K., Louie A.D., Jadhav R.R., Hung C.-N., Wang C.-M., Lin C.-L., Kirma N.B., Liss M.A., Kumar A.P., Sun L.-Z., Liu Z.-J., Chao W.-T., Wang Q.-B., Jin V.X., Chen C.-L., Huang T.H.-M.
Single-cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell-cycle-related transcription and attenuated androgen response.
Cancer Res. 78:853-864(2018)

PubMed=29660373; DOI=10.1016/j.bbagen.2018.04.012
Touat-Hamici Z., Bulteau A.-L., Bianga J., Jean-Jacques H., Szpunar J., Lobinski R., Chavatte L.
Selenium-regulated hierarchy of human selenoproteome in cancerous and immortalized cells lines.
Biochim. Biophys. Acta 1862:2493-2505(2018)

PubMed=29739788; DOI=10.1158/1078-0432.CCR-18-0410; PMCID=PMC6125187
de Leeuw R., McNair C., Schiewer M.J., Poudel-Neupane N., Brand L.J., Augello M.A., Li Z., Cheng L.C., Yoshida A., Courtney S.M., Hazard E.S., Hardiman G., Hussain M.H., Diehl J.A., Drake J.M., Kelly W.K., Knudsen K.E.
MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.
Clin. Cancer Res. 24:4201-4214(2018)

PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132; PMCID=PMC6548687
Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P., Mitra R., Nonn L., Kimbro K.S., Kittles R.A.
Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines.
Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019)

PubMed=35502546; DOI=10.1158/0008-5472.CAN-22-1065; PMCID=PMC9153264
Abate-Shen C., Nunes de Almeida F.
Establishment of the LNCaP cell line -- the dawn of an era for prostate cancer research.
Cancer Res. 82:1689-1691(2022)

PubMed=38892296; DOI=10.3390/ijms25116111; PMCID=PMC11172770
Beatson E.L., Risdon E.N., Napoli G.C., Price D.K., Chau C.H., Figg W.D. Sr.
Genomic characterization of preclinical prostate cancer cell line models.
Int. J. Mol. Sci. 25:6111.1-6111.19(2024)